Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Consistently tracking KL-6 levels may help predict acute exacerbations in IPF and other types of fibrotic ILDs, a study ...

How do you want to be remembered after your passing? Columnist Sam Kirton shares the steps he's taking to leave a positive legacy.

A study found 10 IPF patients given EGCG, a green tea antioxidant, for 14 days had normal levels of pro-fibrotic proteins in lung tissue.

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

The U.S. Food and Drug Administration has granted Bristol Myers Squibb’s investigational therapy BMS-986278 breakthrough therapy status.

IPF treatment SM001-055 was generally safe and improved lung function, according to top-line data from a Phase 2a trial.